Menu

ORI: Researcher Faked Dozens of Experiments

A former scientist at the University of Michigan and the University of Chicago made up more than 70 experiments on heart cells, according to the Office of Research Integrity.

May 25, 2016
Jef Akst

WIKIMEDIA, TIMVICKERS“All told, [Ricky] Malhotra claimed to have conducted 74 experiments that never happened, and falsified well over 100 Western blots,” Retraction Watch reported today (May 25). The former University of Michigan and University of Chicago researcher admitted to the misconduct, which over the course of six years involved three National Institutes of Health (NIH) grant applications and a 2010 manuscript published in the Journal of Biological Chemistry, according to a case summary published this week (May 24) by the Office of Research Integrity (ORI). The agency noted that Malhotra has agreed to retract the JBC paper.

According to his LinkedIn profile, Malhotra worked at an Ann Arbor, Michigan–based  microscopy company called PicoCal and is now serving as cardiovascular and metabolic consultant in the greater Boston area. He told the ORI that he does not plan to apply for any US Public Health Service funding. If he should do so in the next five years, his work will be supervised and he will be required to provide biannual reports to verify the legitimacy of his research, according to the ORI summary.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.